Breaking News

Agilent Technologies Selects Turner to Build $725 Million Manufacturing Plant

The facility will produce oligonucleotide therapeutics to treat cancer, cardiovascular disease.

Agilent Technologies has chosen Turner Construction Company to build a $725 million facility to produce active pharmaceutical ingredients (API) in Frederick, CO. The project is scheduled for completion in 2026. The 200,000 square-foot project will increase Agilent’s capacity to meet demand for the company’s synthetic oligonucleotides, which help treat cancer, cardiovascular disease, and other rare diseases. The project will be built in accordance with Process Safety Management (PSM) standa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters